Search company, investor...
Althea Technologies company logo

Althea Technologies

Founded Year



Acquired | Acquired

Total Raised




About Althea Technologies

Althea Technologies is a San Diego based contract manufacturing organization offering cGMP fill and finish, protein and plasmid DNA manufacturing, lyophilization, stability testing, process development, and a variety of other services for the biotechnology and pharmaceutical industries.In April 2013, Althea Technologies was acquired by Ajinomoto Co. The valuation of Althea Technologies was $175 million. Other terms of the deal were not released.

Headquarters Location

11040 Roselle Street

San Diego, California, 92121,

United States


Missing: Althea Technologies's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Althea Technologies's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing Althea Technologies

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Althea Technologies is included in 1 Expert Collection, including Biopharma Tech.


Biopharma Tech

5,241 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

Althea Technologies Patents

Althea Technologies has filed 1 patent.

patents chart

Application Date

Grant Date


Related Topics




Monoclonal antibodies, Proteins, Clusters of differentiation, Biological research institutes, Immune system


Application Date


Grant Date



Related Topics

Monoclonal antibodies, Proteins, Clusters of differentiation, Biological research institutes, Immune system



Latest Althea Technologies News

AnaptysBio Announces Fourth Quarter and Full Year 2020 Financial Results and Provides Pipeline Updates

Feb 26, 2021

| Source: AnaptysBio, Inc. Positive topline data from GALLOP Phase 2 clinical trial of imsidolimab in moderate to severe generalized pustular psoriasis (GPP) announced in October 2020, with Phase 3 trial initiation anticipated in mid-2021 Topline data from POPLAR Phase 2 imsidolimab clinical trial in palmoplantar pustulosis (PPP) anticipated in Q1 2021 Expansion of imsidolimab program into four additional dermatological inflammatory Phase 2 clinical trials, including EGFRi-mediated skin toxicities, ichthyosis, hidradenitis suppurativa and acne, with top-line data readouts from Phase 2 trials anticipated through 2021 and 2022 Advancement of ANB030 into a healthy volunteer Phase 1 trial with top-line data anticipated in mid-2021 and initiation of Phase 2 clinical trials in alopecia areata and vitiligo in Q4 2021 Amended strategic immuno-oncology collaboration with GlaxoSmithKline (GSK) to increase dostarlimab royalties to 8-25% of global sales, add 1% Zejula™ royalty effective January 2021 and receive additional $60 million cash in Q4 2020 $75MM in cash milestones anticipated from dostarlimab regulatory milestones under GSK collaboration over upcoming 18 months, including US BLA and EU MAA approval for dMMR endometrial cancer anticipated in H1 2021 and acceptance of US BLA for pan-dMMR tumors in Q1 2021 SAN DIEGO, Feb. 25, 2021 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on emerging immune control mechanisms applicable to inflammation and immuno-oncology indications, today reported operating results for the fourth quarter and year ended December 31, 2020 and provided pipeline updates. “We made progress in advancing AnaptysBio’s pipeline during 2020 and look forward to multiple clinical readouts from our wholly-owned programs in 2021. Imsidolimab will continue to be our key focus going forward as we anticipate GPP Phase 3 initiation and Phase 2 topline readouts from five other immune-dermatology indications through 2021 and 2022. We also anticipate commercial launch of dostarlimab this year and meaningful milestone and royalty revenue to AnaptysBio under our GSK partnership,” said Hamza Suria, president and chief executive officer of AnaptysBio. “Our strategy is to continue advancing first-in-class immunology-focused therapeutic antibodies through key clinical data catalysts using a capital-efficient business model.” Imsidolimab (Anti-IL-36 Receptor) Program In July, we announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation for imsidolimab, our proprietary anti-interleukin-36 receptor (IL-36R) antibody, for the treatment of patients with GPP. In October, we announced positive topline data from an interim analysis of our imsidolimab GALLOP Phase 2 trial in GPP. Six of 8 patients achieved the primary endpoint of disease improvement upon Day 29, while erythema with skin pustules, which clinically defines GPP, decreased by 94% on Day 29 relative to baseline. We plan to report 16-week data from the GALLOP trial at a medical conference in 2021. We anticipate initiation of a Phase 3 trial for imsidolimab in GPP during mid-2021 following completion of protocol alignment, and review of 16-week data from the Phase 2 GALLOP trial, with the FDA. We are also conducting a randomized, placebo-controlled, multi-dose Phase 2 trial in 59 patients with palmoplantar pustulosis, or PPP, also known as the POPLAR trial, with topline data anticipated in Q1 2021. We have expanded our imsidolimab program into third and fourth new clinical indications, EGFRi-mediated skin toxicities and ichthyosis, with interim top-line data from Phase 2 trials anticipated at the end of 2021 and in 2022, respectively, and we are also expanding the imsidolimab program into fifth and sixth new clinical indications, hidradenitis suppurativa and acne, with initiation of Phase 2 trials in these indications anticipated in Q2 2021. We initiated a worldwide registry of GPP and PPP patients, named RADIANCE, in Q1 2021, to improve understanding of the patient journey and support enrollment of future trials. ANB030 (Anti-PD-1 Agonist) Program We anticipate topline data from our ongoing Phase 1 healthy volunteer clinical trial of ANB030, our wholly-owned PD-1 agonist antibody, designed to assess the safety, pharmacokinetics and pharmacodynamics of ANB030 in single and multiple ascending dose cohorts in mid-2021. Preclinical translational data using ANB030 was presented in March 2020 at the Festival of Biologics Meeting. We anticipate initiating Phase 2 trials of ANB030 in alopecia areata and vitiligo in Q4 2021. ANB032 (Anti-BTLA Modulator) Program We filed a Clinical Trial Notification (“CTN”) in Australia for ANB032, our wholly-owned BTLA modulator antibody, during the first quarter of 2021 and anticipate initiating a healthy volunteer Phase 1 trial in the first half of 2021 upon clearance of the CTN. We presented preclinical data regarding ANB032 at the 2020 Federation of Clinical Immunology Societies (FOCIS) Virtual Annual Meeting in October 2020. Etokimab (ANB020 Anti-IL-33) Program We discontinued further development of etokimab, our anti-IL-33 antibody previously referred to as ANB020, following review of topline week 16 data from the approximately 100-patient ECLIPSE trial in chronic rhinosinusitis with nasal polyps (CRSwNP), where patients dosed with etokimab every four (q4w) or eight weeks (q8w) failed to achieve statistically significant over placebo on either co-primary endpoint. Dostarlimab (Anti-PD-1 Antagonist) Program Partnered with GSK In October 2020, we amended our immuno-oncology collaboration with GSK resulting in increased financial consideration to AnaptysBio. Royalties due to AnaptysBio for dostarlimab were increased to 8-25% of global net sales, where AnaptysBio will receive 8% of annual global net sales below $1 billion, and 12-25% of net sales above $1 billion. The $1.1 billion in cash milestone payments due under the collaboration agreement remain unchanged, and AnaptysBio anticipates receiving $75 million in such cash milestones over the next 18 months as dostarlimab obtains FDA and EMA regulatory approval for the first two indications. An additional $165 million in sales milestones is anticipated by AnaptysBio upon achievement of certain dostarlimab annual sales revenues. GSK also agreed, starting January 1, 2021, to pay AnaptysBio a 1% royalty on all of GSK’s global net sales of Zejula. In addition, GSK paid AnaptysBio a one-time cash payment of $60 million in Q4 2020. In exchange, AnaptysBio provided GSK with freedom to conduct development and commercialization of Zejula in combination with third-party molecules and settled the dispute between AnaptysBio and GSK. US BLA and European Union EMA approvals for dostarlimab are anticipated for endometrial cancer in H1 2021, which will result in $20 million and $10 million milestone payments, respectively. The FDA recently accepted a subsequent US BLA for dostarlimab in pan-deficient mismatch repair tumors and we anticipate receiving a $10 million payment from GSK in Q1 2021 as a result of this milestone. Board of Directors In January 2021, the Company appointed Dr. Magda Marquet to its board of directors. She is the co-founder of AltheaDx, a commercial stage, precision medicine company, and co-founded Althea Technologies and as its co-CEO led the company to become a highly profitable, commercial company. Prior to starting Althea Technologies, Dr. Marquet held several positions in pharmaceutical development in companies such as Vical and Amylin Pharmaceuticals. She currently serves on the Board of Directors of Arcturus Therapeutics, Micronoma, Matrisys Biosciences and ProciseDx. Fourth Quarter Financial Results Cash, cash equivalents and investments totaled $411.2 million as of December 31, 2020 compared to $428.5 million as of December 31, 2019, for a net decrease of $17.3 million. The decrease relates primarily to cash used for operating activities partially offset by an increase in collaboration revenue of $67.0 million. Collaboration revenue was $60.0 million and $75.0 million for the three and twelve months ended December 31, 2020, which related to milestone payments for successful BLA and MAA filings for dostarlimab and the $60.0 million amendment related payment from GSK, compared to $3.0 million and $8.0 million for the three and twelve months ended December 31, 2019. Research and development expenses were $21.6 million and $80.0 million for the three and twelve months ended December 31, 2020, compared to $21.4 million and $99.3 million for the three and twelve months ended December 31, 2019. The annual decrease was due primarily to reduced outside services for manufacturing and clinical activities based on the timing of projects. General and administrative expenses were $5.1 million and $18.9 million for the three and twelve months ended December 31, 2020, compared to $3.8 million and $16.1 million for the three and twelve months ended December 31, 2019. The increase was due primarily to increased legal and insurance expenses. Net income was $33.6 million for the three months ended December 31, 2020, or a net income per share of $1.23 and a net loss of $19.9 million for the twelve months ended December 31, 2020, or a net loss per share of $0.73, compared to a net loss of $20.3 million and $97.3 million for the three and twelve months ended December 31, 2019, or a net loss per share of $0.75 and $3.60. Financial Guidance AnaptysBio expects its net cash burn in 2021 will be close to $100 million. We anticipate that our cash, cash equivalents and anticipated revenues will fund our current operating plan at least into 2024. About AnaptysBio AnaptysBio is a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on emerging immune control mechanisms applicable to inflammation and immuno-oncology indications. The Company’s proprietary anti-inflammatory pipeline includes its anti-IL-36R antibody imsidolimab, previously referred to as ANB019, for the treatment of rare inflammatory diseases, including generalized pustular psoriasis, or GPP, palmoplantar pustulosis, or PPP, EGFRi, ichthyosis, hidradenitis suppurativa and acne; its anti-PD-1 agonist program, ANB030, for treatment of certain autoimmune diseases where immune checkpoint receptors are insufficiently activated; and its BTLA modulator program, ANB032, which is broadly applicable to human inflammatory diseases associated with lymphoid and myeloid immune cell dysregulation. AnaptysBio’s antibody pipeline has been developed using its proprietary somatic hypermutation, or SHM platform, which uses in vitro SHM for antibody discovery and is designed to replicate key features of the human immune system to overcome the limitations of competing antibody discovery technologies. AnaptysBio has also developed multiple therapeutic antibodies in an immuno-oncology collaboration with GlaxoSmithKline, including an anti-PD-1 antagonist antibody (dostarlimab GSK4057190A), an anti-TIM-3 antagonist antibody (cobolimab, GSK4069889A) and an anti-LAG-3 antagonist antibody (GSK4074386), and an inflammation collaboration with Bristol-Myers Squibb, including an anti-PD-1 checkpoint agonist antibody (CC-90006) currently in clinical development. Forward-Looking Statements This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to: the timing of the release of data from our clinical trials, including imsidolimab’s Phase 2 clinical trial in PPP, imsidolimab’s Phase 2 clinical trials in EGFRi, ichthyosis, hidradenitis suppurativa, and acne, and ANB030’s Phase 1 healthy volunteer clinical trial; the timing of initiation of imsidolimab’s Phase 2 clinical trials in hidradenitis suppurativa and acne; the timing of initiation of imsidolimab’s Phase 3 clinical trial in GPP; the timing of initiation of ANB032’s Phase 1 healthy volunteer clinical trial; the milestones and royalty payments to be received under the GSK collaboration; and our projected 2021 cash burn and cash runway. Statements including words such as “plan,” “continue,” “expect,” or “ongoing” and statements in the future tense are forward-looking statements. These forward-looking statements involve risks and uncertainties, as well as assumptions, which, if they do not fully materialize or prove incorrect, could cause our results to differ materially from those expressed or implied by such forward-looking statements. Forward-looking statements are subject to risks and uncertainties that may cause the company’s actual activities or results to differ significantly from those expressed in any forward-looking statement, including risks and uncertainties related to the company’s ability to advance its product candidates, obtain regulatory approval of and ultimately commercialize its product candidates, the timing and results of preclinical and clinical trials, the company’s ability to fund development activities and achieve development goals, the company’s ability to protect intellectual property and other risks and uncertainties described under the heading “Risk Factors” in documents the company files from time to time with the Securities and Exchange Commission. These forward-looking statements speak only as of the date of this press release, and the company undertakes no obligation to revise or update any forward-looking statements to reflect events or circumstances after the date hereof. Contact:

Althea Technologies Frequently Asked Questions (FAQ)

  • When was Althea Technologies founded?

    Althea Technologies was founded in 1998.

  • Where is Althea Technologies's headquarters?

    Althea Technologies's headquarters is located at 11040 Roselle Street, San Diego.

  • What is Althea Technologies's latest funding round?

    Althea Technologies's latest funding round is Acquired.

  • How much did Althea Technologies raise?

    Althea Technologies raised a total of $43.1M.

  • Who are the investors of Althea Technologies?

    Investors of Althea Technologies include Ajinomoto, Hercules Capital and Telegraph Hill Partners.

  • Who are Althea Technologies's competitors?

    Competitors of Althea Technologies include CMC Biologics, Algaen, Irvine Pharmaceutical Services, Vandalia Research, Silicon Valley Technology Center, Nexus Dx, Alpha Biologics, Laureate Pharma, Sloning BioTechnology, NanoImaging Services and 13 more.

Compare Althea Technologies to Competitors

Plexus Ventures Logo
Plexus Ventures

The company provide business development services to clients in the pharmaceutical, biotechnology, consumer health, and drug delivery industries worldwide. The company's team members represent an array of nationalities and a mix of commercial, manufacturing, medical, and scientific expertise, gained from decades of experience with both global pharmaceutical and development-stage companies

Angel Biotechnology

Angel Biotechnology Holdings PLC (AIM: ABH) is a world class, contract biomanufacturing company offering process development services and pre-GMP and cGMP manufacturing to support biotechnology and pharmaceutical companies worldwide. Angel's principal activity is the manufacture and supply of materials for use in early stage drug development and pre-clinical studies, along with drug product and CMC documentation for Phases I, II and III clinical trials and the manufacture of licensed drugs or vaccines. nnAngel is managed by a team that has more than 100 years' combined experience in pharmaceutical and biopharmaceutical manufacture, gained in companies such as Glaxo and Serologicals Inc. nnAngel operates out of Pentlands Science Park, near Edinburgh.

Laureate Pharma

Laureate Pharma, Inc. is a full service contract manufacturing organization(CMO) providing development and cGMP manufacturing services in the company's FDA registered facilities in Princeton, New Jersey. The company is dedicated to supporting the development and commercialization of biopharmaceutical, drug and diagnostic products for pharmaceutical, diagnostic and biotech companies.The company aims to provide a range of product development and manufacturing services from cell line optimization and process design to development of full-scale cGMP protein production, purification and aseptic filling, in addition to corresponding testing, validation, analytical and regulatory support. The company's focus is on mammalian cell based monoclonal antibody and recombinant protein production for clinical and modest commercial supply.The company view the company's customers as partners and provide them with flexible solutions that reduce time to clinic and market. Focused on operational excellence, the company's highly experienced staff works with the company's customers to improve the quality of their products and processes.The company value the company's customers, stakeholders and associates. Therefore, the company measure the company's success by meeting the company's customers' needs, generating results in terms of quality, timeliness and on budget performance, as well as fostering an environment of trust, growth and diversity for the company's team.


SiTec Consulting was established in 1996, on the basis of long experience in pharmaceutical R&D. The company developed a range of expertise working with pharmaceutical and biotech companies in the United States and in Europe.n SiTec Consulting offers pharmaceutical and biotechnology companies a variety of services in the areas of preformulation, drug development, drug delivery and formulation technologies evaluation, regulatory and cGLP/cGMP compliance. The company can actively collaborate with start-up pharmaceutical and drug delivery companies to provide scientific and strategic support in the establishment of the new company's activities. The company emphasize open communication, active involvement with the client and continuous feedback.n Networking is one of the company's assets, allowing us to cover the complex demands of the R&D process. The company have access to laboratories and equipment and resources, located at the Bioindustry Park Canavese, and at selected universities and research centers in Europe. This aims to give the possibility to conduct and manage experimental parts of projects at the company's clients' request.n The company value the importance of high quality training. In addition to the hands-on experience the company can provide to the company's clients, SiTec is an authorized representative of the Center for Professional Advancement, a worldwide private institution dedicated to the provision of continuing technical and scientific education at a professional level.


Kryosphere provides customized biorepository, logistical, and clinical sample management services to companies with a critical biospecimen component. Kryosphere delivers secure, scalable solutions to customers ranging from small, emerging entities to large corporations worldwide.

Hylobates Consulting srl

Hylobates Consulting s.r.l. is company that aims to provide consulting in risk and safety. The company collaborate with businesses in the food, cosmetic, food supplement and biotechnology industries so that they can achieve high margins of safety for their products. The company's services are based on the best and latest available science and technology, on the company's actual experience and oriented to fulfilling the needs of the company's customers. The company specialize in the HACCP method, with a set of consulting services, that includes allergen management. Other services include risk analyses for foodborne hazards.nIn the area of biosafety, the company assess and analyze risks for GMOs and GMMs, the company design sampling plans and strategies to control or prevent cross-contamination and for coexistence.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.